Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Phase 2/3 × Has announcements × 90 days × Clear all

Phase

Phase 3 69 Phase 2 25 Phase 1/2 15 Phase 1 4 Phase 2/3 2

Status

Active not recruiting 2

Sponsor Class

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1 Breast 1

Conditions

Recurrence 1 Myelodysplastic Syndromes 1 Breast Neoplasms 1

Interventions

palbociclib 1 inavolisib 1 imetelstat 1 GRN163L peptide 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04191499 2026-03-17

INAVO120

Hoffmann-La Roche

Phase 2/3 Active not recruiting

325 enrolled 14 charts 1 FDA

Breast Neoplasms

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Geron Corporation

Phase 2/3 Active not recruiting

289 enrolled 35 charts 1 FDA

Myelodysplastic Syndromes, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡